-
Mashup Score: 0
Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
The FDA has granted priority review to the sBLA seeking the approval of durvalumab for muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Grants Priority Review to Durvalumab for Muscle-Invasive Bladder Cancer #blcsm #oncology https://t.co/17Z9hIugtA
-
-
Mashup Score: 0
The FDA has granted priority review to the sBLA seeking the approval of durvalumab for muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Grants Priority Review to Durvalumab for Muscle-Invasive Bladder Cancer #blcsm #oncology https://t.co/17Z9hIugtA
-
-
Mashup Score: 0
The FDA has granted priority review to the sBLA seeking the approval of durvalumab for muscle-invasive bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Grants Priority Review to Durvalumab for Muscle-Invasive Bladder Cancer #blcsm #oncology https://t.co/17Z9hIugtA
-
-
Mashup Score: 3TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer - 2 month(s) ago
TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer #blcsm #oncology https://t.co/mhACnw8aMq
-
-
Mashup Score: 0Investigative Targeted Agents Are Set to Expand the BCG-Unresponsive NMIBC Treatment Paradigm - 2 month(s) ago
Yair Lotan, MD, discusses notable up-and-coming agents in the BCG-unresponsive non–muscle-invasive bladder cancer treatment armamentarium.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Investigative Targeted Agents Are Set to Expand the BCG-Unresponsive NMIBC Treatment Paradigm @UTSWMedCenter #blcsm #oncology https://t.co/Hy4gvaF5CO
-
-
Mashup Score: 3TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer - 2 month(s) ago
TYRA-300 was safe and produced antitumor activity in metastatic urothelial cancer harboring FGFR3 alterations.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer #blcsm #oncology https://t.co/mhACnw8aMq
-
-
Mashup Score: 2Investigative Targeted Agents Are Set to Expand the BCG-Unresponsive NMIBC Treatment Paradigm - 2 month(s) ago
Yair Lotan, MD, discusses notable up-and-coming agents in the BCG-unresponsive non–muscle-invasive bladder cancer treatment armamentarium.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Investigative Targeted Agents Are Set to Expand the BCG-Unresponsive NMIBC Treatment Paradigm @UTSWMedCenter #blcsm #oncology https://t.co/Hy4gvaF5CO
-
-
Mashup Score: 2ADCs Usher in a Complex New Era of Disease and Toxicity Management in Bladder Cancer - 3 month(s) ago
Jacqueline Brown, MD, discusses the nuanced potential role of immunotherapy-ADC and dual-ADC combinations in bladder cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The toxicity profiles associated with ADCs reinforce the importance of stringent patient selection to identify the most fit patients for these therapies in bladder cancer. @jackiebrown_md @WinshipAtEmory #blcsm #oncology https://t.co/XAHowGfdbX https://t.co/MAd7ZpxmLd
-
-
Mashup Score: 6Cisplatin’s Prevalence in Bladder Cancer Falters With the Introduction of Enfortumab Vedotin - 3 month(s) ago
Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Cisplatin’s Prevalence in Bladder Cancer Falters With the Introduction of Enfortumab Vedotin @jackiebrown_MD @winshipatemory @emorymedicine #blcsm #oncology https://t.co/6ai9v1hkr2
-
Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC @CURCMB #blcsm #oncology https://t.co/EPRAagpGnA